findmyKOL
Clinical trialNCT02442492TerminatedPhase 2/PHASE3Interventional

Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction

SponsorUniversity of British ColumbiaEnrollment21Fetal Growth Restriction (FGR)Intrauterine Growth Restriction (IUGR)
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Early-onset placental intrauterine growth restriction (EO IUGR) is associated with a high risk of perinatal morbidity and mortality. In association with reduced circulating placental growth factor (PlGF) EO IUGR results from abnormal placentation with inadequate remodelling of the maternal uteroplacental arteries. There is no known treatment for placental IUGR. Management involves intensive fetal surveillance with delivery with evidence of serious fetal compromise. However, remote from term, delivery is associated with significant perinatal mortality and morbidity. Sildenafil vasodilates the uteroplacental vessels of IUGR-affected pregnancies and may represent a novel therapy.

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

  • Kenneth Lim, MD FRCSC

    University of British Columbia

    Principal Investigator
  • Peter von Dadelszen, BMedSc, MBChB, DipObst, DPhil,

    University of British Columbia

    Principal Investigator

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • Royal Alexandra Hospital

    Edmonton, Alberta, Canada

  • Bc Women'S Hospital/university of British Columbia

    Vancouver, British Columbia, Canada

  • London Health Sciences Centre

    London, Ontario, Canada

  • Chu Sainte-Justine

    Montreal, Quebec, Canada

  • Chu de Quebec - Universite Laval

    Québec, Quebec, Canada

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jan 2017
Primary completion
31 Jul 2018
Completion
30 Apr 2019
Last update posted
11 Feb 2020
Registered enrollment
21
Registry id
NCT02442492

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.